Edward L Tobinick

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases
    Edward Tobinick
    Institute for Neurological Research, a private medical group, Inc, Los Angeles, California, USA
    CNS Drugs 25:145-55. 2011
  2. ncbi Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease
    Edward Tobinick
    100 UCLA Medical Plaza, Suites 205 210, Los Angeles, California 90095, USA
    Curr Alzheimer Res 9:99-109. 2012
  3. doi Perispinal etanercept: a new therapeutic paradigm in neurology
    Edward Tobinick
    David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suites 205 210, Los Angeles, CA 90095, USA
    Expert Rev Neurother 10:985-1002. 2010
  4. doi Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence
    Edward Tobinick
    Institute for Neurological Research, Los Angeles, California 90095, USA
    CNS Drugs 23:713-25. 2009
  5. doi The value of drug repositioning in the current pharmaceutical market
    Edward L Tobinick
    Medicine at the University of California, Los Angeles, CA, USA
    Drug News Perspect 22:119-25. 2009
  6. pmc Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging
    Edward L Tobinick
    Institute for Neurological Research, a private medical group, Inc, 100 UCLA Medical Plaza, Suites 205 210, Los Angeles, California 90095 USA
    BMC Res Notes 2:28. 2009
  7. doi Perispinal etanercept for neuroinflammatory disorders
    Edward Tobinick
    Institute for Neurological Research, a private medical group, inc 100 UCLA Medical Plaza, Suites 205 210, Los Angeles, CA 90095, United States
    Drug Discov Today 14:168-77. 2009
  8. pmc Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism
    Edward Tobinick
    University of California Los Angeles Institute for Neurological Research, Los Angeles, California, USA
    Medscape J Med 10:135. 2008
  9. pmc Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease
    Edward L Tobinick
    Institute for Neurological Research, a private medical group, Inc, Los Angeles, USA
    BMC Neurol 8:27. 2008
  10. ncbi Perispinal etanercept for treatment of Alzheimer's disease
    Edward Tobinick
    100 UCLA Medical Plaza, Suites 205 210, Los Angeles, California 90095, USA
    Curr Alzheimer Res 4:550-2. 2007

Detail Information

Publications16

  1. doi Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases
    Edward Tobinick
    Institute for Neurological Research, a private medical group, Inc, Los Angeles, California, USA
    CNS Drugs 25:145-55. 2011
    ..Perispinal administration of etanercept, previously reported to be beneficial for the treatment of Alzheimer's disease, may facilitate delivery of etanercept into the brain...
  2. ncbi Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease
    Edward Tobinick
    100 UCLA Medical Plaza, Suites 205 210, Los Angeles, California 90095, USA
    Curr Alzheimer Res 9:99-109. 2012
    ..CSF-contacting cells may constitute a therapeutic target for a diverse group of brain, psychiatric and spinal disorders...
  3. doi Perispinal etanercept: a new therapeutic paradigm in neurology
    Edward Tobinick
    David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suites 205 210, Los Angeles, CA 90095, USA
    Expert Rev Neurother 10:985-1002. 2010
    ..The scientific rationale, physiologic mechanisms, clinical effects and potential clinical indications of this therapeutic approach are the subject of this article...
  4. doi Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence
    Edward Tobinick
    Institute for Neurological Research, Los Angeles, California 90095, USA
    CNS Drugs 23:713-25. 2009
    ..Perispinal etanercept for AD merits further study in randomized clinical trials...
  5. doi The value of drug repositioning in the current pharmaceutical market
    Edward L Tobinick
    Medicine at the University of California, Los Angeles, CA, USA
    Drug News Perspect 22:119-25. 2009
    ..For these reasons, repurposing should be a primary strategy in drug discovery for every broadly focused, research-based pharmaceutical company...
  6. pmc Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging
    Edward L Tobinick
    Institute for Neurological Research, a private medical group, Inc, 100 UCLA Medical Plaza, Suites 205 210, Los Angeles, California 90095 USA
    BMC Res Notes 2:28. 2009
    ..Further study of the effects of etanercept and TNF at the level of the choroid plexus may yield valuable insights into the pathogenesis of Alzheimer's disease...
  7. doi Perispinal etanercept for neuroinflammatory disorders
    Edward Tobinick
    Institute for Neurological Research, a private medical group, inc 100 UCLA Medical Plaza, Suites 205 210, Los Angeles, CA 90095, United States
    Drug Discov Today 14:168-77. 2009
    ....
  8. pmc Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism
    Edward Tobinick
    University of California Los Angeles Institute for Neurological Research, Los Angeles, California, USA
    Medscape J Med 10:135. 2008
    ..Further study of this therapeutic method is indicated...
  9. pmc Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease
    Edward L Tobinick
    Institute for Neurological Research, a private medical group, Inc, Los Angeles, USA
    BMC Neurol 8:27. 2008
    ....
  10. ncbi Perispinal etanercept for treatment of Alzheimer's disease
    Edward Tobinick
    100 UCLA Medical Plaza, Suites 205 210, Los Angeles, California 90095, USA
    Curr Alzheimer Res 4:550-2. 2007
    ....
  11. pmc Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration
    Edward L Tobinick
    Department of Medicine, Institute for Neurological Research, Los Angeles, USA
    J Neuroinflammation 5:2. 2008
    ....
  12. pmc TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study
    Edward Tobinick
    University of California, Los Angeles, California, USA
    MedGenMed 8:25. 2006
    ..Current pharmacologic treatments for Alzheimer's disease (AD) do not prevent long-term clinical deterioration. Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD...
  13. ncbi Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients
    Edward Tobinick
    Institute Research Associates, A Medical Group, Inc, Los Angeles, CA, USA
    Curr Med Res Opin 20:1075-85. 2004
    ..Documentation of the clinical results obtained utilizing perispinal etanercept off-label for treatment-refractory back and neck pain in a clinical practice setting...
  14. ncbi Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports
    Edward Lewis Tobinick
    Institute for Neurological Research, Los Angeles, California 90095, USA
    Clin Ther 25:2279-88. 2003
    ..Additional studies have implicated TNF-alpha in the promotion of osteoclast-mediated malignant osteolysis and the pathogenesis of neuropathic pain. TNF-alpha antagonists have the potential to interfere in both processes...
  15. ncbi Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults
    Edward L Tobinick
    Institute Research Associates, A Medical Group, Inc, Los Angeles, California 90095, USA
    Clin Ther 25:1211-8. 2003
    ..Directed local administration of etanercept, in anatomic proximity to the site of disc and neuronal abnormality, may result in an enhanced therapeutic response...
  16. ncbi Perispinal TNF-alpha inhibition for discogenic pain
    Edward L Tobinick
    Institute for Neurological Research, Los Angeles, California, USA
    Swiss Med Wkly 133:170-7. 2003
    ..To examine the potential of etanercept, a biological inhibitor of tumour necrosis factor-alpha (TNF), delivered by perispinal administration, for the treatment of pain associated with intervertebral disc disease...